Biolegend, 100701, Purified anti-mouse CD8a Antibody, 50μg

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.
50μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Mouse thymus or spleen
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/mL
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: FC - Quality tested CyTOF®, IHC-F - Verified IP - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µL volume. For immunohistochemistry on frozen tissue sections, the suggested use of this reagent is 5.0 - 10 µg per mL. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).
Application References(PubMed link indicates BioLegend citation): Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP) Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete) Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP) Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block) Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC) Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC) Shih FF, et al. 2006. J. Immunol. 176:3438. (FC) Kamimura D, et al. 2006. J. Immunol. 177:306. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete) Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed Lee CH, et al. 2009. Clin. Cancer Res. PubMed Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed Guo Y, et al. 2008. Blood 112:480. PubMed Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed Kenna TJ, et al. 2008. Blood 111:2091. PubMed Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed Medyouf H, et al. 2010. Blood 115:1175. PubMed Riedl P, et al. 2009. J. Immunol. 183:370. PubMed Apte SH, et al. 2010. J. Immunol. 185:998. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed Cui L, et al. 2015. J Control Release. 206:220. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Dallari S, et al. 2017. Nat Commun. 8:14830. PubMed Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed Arnold IC, et al. 2019. PLoS Pathog. 15:e1007866. PubMed Corria-Osorio J, et al. 2023. Nat Immunol. 24:869. PubMed Kang YA, et al. 2023. J Exp Med. 220:. PubMed Xu J, et al. 2023. Discov Oncol. 14:68. PubMed Kobayashi A, et al. 2021. Front Immunol. 12:650856. PubMed Tersteegen A, et al. 2021. Infect Immun. 89:. PubMed Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed Yu H, et al. 2020. Front Immunol. 11:1773. PubMed Malinczak CA, et al. 2021. J Immunol. 206:1315. PubMed Li H, et al. 2022. Cancer Cell. 40:36. PubMed Campisi L, et al. 2022. Nature. 606:945. PubMed Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed Gerace D, et al. 2023. Cell Rep Med. 4:100879. PubMed Jeon EY, et al. 2023. Bioeng Transl Med. 8:e10362. PubMed Potempa M, et al. 2022. J Immunol. 208:1742. PubMed Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed Kao C, et al. 2005. Int Immunol. 1.824305556. PubMed Krovi SH, et al. 2019. Proc Natl Acad Sci U S A. 116:22252. PubMed Thelin MA, et al. 2017. Diabetes. 66:2220. PubMed Thi VAD, et al. 2019. Mol Cells. 42:869. PubMed Asthagiri Arunkumar G, et al. 2019. Vaccine. 37:5567. PubMed Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed Chartrand K, et al. 2018. Front Immunol. 1.642361111. PubMed Bajaña S, et al. 2021. Front Immunol. 11:577718. PubMed Murata A, et al. 2020. Front Immunol. 11:775. PubMed Wang C, et al. 2020. Oncoimmunology. 9:1809947. PubMed Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed Rubio‐Patiño C et al. 2018. Cell metabolism. 27(4):828-842 . PubMed Rieck M, et al. 2017. Eur J Immunol. 47:677. PubMed Goel S, et al. 2017. Nature. 548:471. PubMed Bradford BM, et al. 2018. Parasite Immunol. 40:e12566. PubMed Field CS, et al. 2018. Oncoimmunology. 7:e1376154. PubMed Wang W, et al. 2018. Cancer Cell. 34:757. PubMed Boldison J, et al. 2020. Cell Mol Immunol. 17:843. PubMed Prado C, et al. 2021. J Neuroinflammation. 18:292. PubMed Carpenter SM, et al. 2017. PLoS Pathog. 13:e1006704. PubMed Gao J, et al. 2017. Oncol Lett. 14:2954. PubMed Haque M, et al. 2021. Viruses. 13:. PubMed Mayer JU, et al. 2020. Front Immunol. 11:592325. PubMed Tian K, et al. 2021. J Immunol Res. 2021:6297332. PubMed Nguyen N, et al. 2022. iScience. 25:103679. PubMed Hirano J, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed Draganov D, et al. 2021. NPJ Breast Cancer. 7:22. PubMed Rossi DC, et al. 2021. J Clin Invest. 131:. PubMed Zhou AC, et al. 2017. Front Immunol. 1.136111111. PubMed Ma C, et al. 2018. Science. 360:eaan5931. PubMed Kaplanov I, et al. 2019. Proc Natl Acad Sci U S A. 116:1361. PubMed Niss Arfelt K, et al. 2017. Blood. 129:866. PubMed Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed Willimsky G, et al. 2021. Elife. 10:. PubMed Tian D, et al. 2020. FASEB J. 34:3367. PubMed Stefanescu C, et al. 2021. Front Oncol. 11:765151. PubMed McLeod RL, et al. 2018. Oncotarget. 9:34459. PubMed Bartsch YC, et al. 2018. Front Immunol. 1.196527778. PubMed Morabito KM, et al. 2017. Mucosal Immunol. 0.795138889. PubMed Recino A, et al. 2019. Gene Ther. 26:40. PubMed Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed Peng V, et al. 2020. J Biol Chem. 295:14866. PubMed Yang M, et al. 2020. Oncoimmunology. 9:1708064. PubMed Hiramatsu-Asano S, et al. 2021. Front Immunol. 11:616141. PubMed Doorduijn EM, et al. 2018. Front Immunol. 0.416666667. PubMed Sun H, et al. 2018. J Cell Biol. 217:1453. PubMed Chen S, et al. 2018. Immunohorizons. 0.345138889. PubMed Guo Y, et al. 2008. Blood. 112:480. PubMed Wang N, et al. 2021. Mol Ther Oncolytics. 20:71. PubMed Suzuki Y, et al. 2021. FEBS Open Bio. 11:2619. PubMed Yan J, et al. 2020. Cancer Immunol Res. 8:356. PubMed Chen L, et al. 2020. Front Immunol. 11:584458. PubMed Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed Yang SH, et al. 2017. Front Immunol. 8:1192. PubMed Zhao L, et al. 2018. Nat Med. 24:1536. PubMed Hiratsuka S, et al. 2018. EMBO Mol Med. 10:e8643. PubMed Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed Sharma M, et al. 2020. Nat Commun. 11:661. PubMed Mori H, et al. 2015. Toxicol Pathol. 43: 883-889. PubMed Gozgit JM, et al. 2021. Cancer Cell. :. PubMed Lasso P, et al. 2020. Front Immunol. 584959:11. PubMed Furukawa K,et al. 2017. PLoS One. 10.1371/journal.pone.0184901. PubMed Zhao F, et al. 2018. Cancer Immunol Res. 1.263194444. PubMed Gartlan KH, et al. 2019. Blood Adv. 2.110416667. PubMed Abboud G, et al. 2018. Front Immunol. 9:1973. PubMed Sharba S, et al. 2019. Virulence. 10:97. PubMed Xie D, et al. 2020. Eur J Immunol. 50:1729. PubMed Liu H, et al. 2020. J Immunol. 205:1207. PubMed Brown IK, et al. 2021. PLoS Pathog. 17:e1009602. PubMed Zhong X, et al. 2020. Proc Natl Acad Sci U S A. 8563:117. PubMed Zareie P, et al. 2017. J Neuroinflammation. 0.630555556. PubMed Kim SJ, et al. 2017. Nat Immunol. 18:1016. PubMed Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed Hoves S, et al. 2018. J Exp Med. 215:859. PubMed Hsiao CC, et al. 2021. Cells. 10:. PubMed Dooley K, et al. 2021. Mol Ther. 29:1729. PubMed Dai Z, et al. 2021. JCI Insight. 6: . PubMed Sprouse ML, et al. 2018. JCI Insight. 3:e97322. PubMed Lee JY, et al. 2018. Front Immunol. 0.678472222. PubMed Sheppard S, et al. 2018. Front Immunol. 1.630555556. PubMed Sharabi A, et al. 2019. JCI Insight. 4:e126294. PubMed Chihara N, et al. 2018. Nature. 558:454. PubMed Shin J, et al. 2018. Diabetes. 67:1068. PubMed Majer O, et al. 2019. Nature. 575:366. PubMed Tao H, et al. 2021. Front Immunol. 12:623280. PubMed Jang SC, et al. 2021. Commun Biol. 4:497. PubMed You X, et al. 2022. Front Genet. 12:790990. PubMed Zelazowska MA, et al. 2020. Life Sci Alliance. :3. PubMed Murakami R, et al. 2013. PLoS One. 8:73270. PubMed Kenna T, et al. 2008. Blood. 111:2091. PubMed King IL, et al. 2017. Mucosal Immunol. 10:1160. PubMed Yates K, et al. 2018. Proc Natl Acad Sci U S A. 115:2162. PubMed Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed Oyarce K, et al. 2018. Front Immunol. 9:112. PubMed Gilfillan CB, et al. 2020. Eur J Immunol. 50:505. PubMed Chen HW, et al. 2021. Biomedicines. 9:. PubMed Tan CL, et al. 2018. Immunohorizons. 0.248611111. PubMed Mensurado S, et al. 2018. PLoS Biol. 16:e2004990. PubMed Yoon BH, et al. 2018. Mol Cells. 41:953. PubMed Ikezoe T, et al. 2021. Biomolecules. 11:. PubMed Li J, et al. 2021. Front Immunol. 12:710406. PubMed Dionisio-Santos DA, et al. 2021. Front Neurosci. 15:758677. PubMed Bajic D, et al. 2020. Mol Cancer Ther. 19:2554. PubMed Goh W, et al. 2020. Cell Rep. 33:108285. PubMed Kakaradov B, et al. 2017. Nat Immunol. 18:422. PubMed Kim D, et al. 2019. Immune Netw. 19:e32. PubMed Rosenbaum M, et al. 2019. Nat Commun. 2.05. PubMed Meyers JL, et al. 2018. PLoS One. 13:e0207007. PubMed Kawabe T, et al. 2017. Sci Immunol. 2:eaam9315. PubMed Seo SU, et al. 2021. Front Immunol. 12:697162. PubMed Duncan CG, et al. 2018. G3 (Bethesda). 0.892361111. PubMed Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed Ko S, et al. 2005. J Immunol. 175:3309. PubMed Shissler SC, et al. 2020. Sci Rep. 10:8218. PubMed Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed Brownlie D, et al. 2021. J Immunother Cancer. 9:. PubMed Tsai MS, et al. 2021. Int J Mol Sci. 22:. PubMed Zhang Z, et al. 2020. Front Immunol. 1.844444444. PubMed Brown ZJ, et al. 2018. Cell Death Dis. 0.805555556. PubMed Stelekati E, et al. 2018. Cell Rep. 2.445833333. PubMed Cui X, et al. 2017. J Immunol. 199:4066. PubMed Lin Z, et al. 2021. Stem Cells. 39:240. PubMed Amobi-McCloud A, et al. 2021. Front Immunol. 12:678999. PubMed Sami E, et al. 2020. Cancer Res. 80:1102. PubMed Zhang C, et al. 2018. Cell Res. 28:323. PubMed Afzali B, et al. 2017. Nat Immunol. 18:813. PubMed Lee YJ, et al. 2018. Front Microbiol. 9:83. PubMed Satoh–Takayama N, et al. 2020. Immunity. 52(4):635-649. PubMed Lee B, et al. 2019. Front Immunol. 0.561805556. PubMed Dey P, et al. 2020. Cancer Discov. 10:608. PubMed Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed Udumula MP, et al. 2021. Mol Metab. 53:101272. PubMed Freed-Pastor WA, et al. 2021. Cancer Cell. 39:1342. PubMed Fujimura N, et al. 2016. J Vasc Surg. 64: 46-54. PubMed Englezou PC, et al. 2018. Mol Ther Nucleic Acids. 12:118. PubMed Cole C, et al. 2018. Nucleic Acids Res. 46:e62. PubMed Sutherland APR, et al. 2019. Sci Rep. 9:15302. PubMed Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed Pittala S, et al. 2018. Neoplasia. 9:20222. PubMed Lin J, et al. 2017. Nat Commun. . 10.1038/s41467-017-01477-5. PubMed Huppé CA, et al. 2018. Mucosal Immunol. 0.536111111. PubMed Kang JG, et al. 2020. PLoS Negl Trop Dis. 14:e0007813. PubMed Gorgun FM, et al. 2021. Front Oncol. 11:701968. PubMed Cui L, et al. 2015. J Control Release. 206:220. PubMed Lee YJ, et al. 2018. FASEB J. 32:4658. PubMed Atif SM, et al. 2019. JCI Insight. 4:e125494. PubMed Khameneh HJ, et al. 2017. J Immunol. 198:196. PubMed Zhang J, et al. 2019. Onco Targets Ther. 12:4985. PubMed Genton C, et al. 2006. J Immunol. 177:2285. PubMed Jordan J, et al. 2008. Infect Immun. 76:3717. PubMed Cong L, et al. 2021. Breast Cancer Res. 23:51. PubMed Zhang N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed Song M, et al. 2020. Nat Commun. 11:6298. PubMed Liu H, et al. 2022. Animal Model Exp Med. 5:72. PubMed Shao Y, et al. 2017. Onco Targets Ther. 10:2675. PubMed Fritz Y, et al. 2017. J Invest Dermatol. 137:696. PubMed Chen YQ, et al. 2019. J Immunother Cancer. 0.415277778. PubMed He X, et al. 2017. Cancer Biol Ther. 0.815277778. PubMed Kästele V, et al. 2021. Mucosal Immunol. 14:717. PubMed Prabakaran T, et al. 2021. EBioMedicine. 66:103314. PubMed Sutiwisesak R, et al. 2020. PLoS Pathog. 16:e1009000. PubMed
RRID: AB_312740 (BioLegend Cat. No. 100701) AB_312741 (BioLegend Cat. No. 100702)
Structure: Ig superfamily, CD8α chain, 34 kD
Distribution: Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
Function: Co-receptor for TCR
Ligand/Receptor: MHC class I molecule
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Zamoyska R. 1994. Immunity 1:243. 3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.
Gene ID: 12525
UniProt: View information about CD8alpha on UniProt.org
Clone: 53-6.7
Regulatory Status: RUO
Other Names: T8, Lyt2, Ly-2
Isotype: Rat IgG2a, κ